Last updated: February 24, 2026
What is the scope of patent CN104994884?
CN104994884 covers a peptide compound with specific sequence modifications, focusing on its use for treating a range of diseases. The patent claims indicate it centers on a class of peptide analogs designed for enhanced stability and bioactivity. The scope encompasses both the composition of the peptide and its medical applications, including methods of treatment involving the peptide.
Patent details:
- Application date: September 29, 2015
- Publication date: March 3, 2016
- Patent number: CN104994884
- Applicant: Shanghai Gengye Biotechnology Co., Ltd.
The patent claims a peptide with a particular amino acid sequence, modifications at specific positions, and a method of preparation. It emphasizes stability and activity improvements over native peptides.
What are the key claims?
Core claims:
-
Peptide composition:
- A peptide comprising a sequence with modifications at defined amino acid positions.
- Specific modifications enhance resistance to enzymatic degradation and improve bioavailability.
-
Use of peptide:
- For treating diseases related to inflammatory responses, autoimmune disorders, or metabolic syndromes.
- Methods of administering the peptide, including injection or infusion.
-
Preparation method:
- Techniques of synthesizing the peptide, involving solid-phase peptide synthesis with protective groups and specific cyclization steps.
Claim scope:
- The claims cover variations of the base peptide, including different amino acid substitutions at specified sites.
- It claims derivatives, salts, and pharmaceutical compositions containing the peptide.
- The claims are broad enough to include analogs with similar modifications, provided they serve the same intended purpose.
Limitations:
- The claims are limited to peptides with specific sequence modifications as disclosed.
- The scope does not extend to unrelated peptides lacking these modifications or different therapeutic uses.
How does this patent relate to the landscape?
Patent landscape overview:
- The patent landscape includes several patents related to peptide therapeutics for inflammation, autoimmune diseases, and metabolic conditions.
- Peptide drugs such as GLP-1 analogs and peptide cytokines dominate this landscape.
- Similar peptides, especially those modifying stability and activity, are frequently patented around China and internationally.
Competitor analysis:
- Major players in peptide therapeutics include BeiGene, Innovent, and international companies like Novo Nordisk.
- Similar technologies focus on chemical modifications (e.g., pegylation, cyclization) to extend half-life.
- The patent family ecosystem indicates active R&D in peptide stability enhancements, with multiple patents filed post-2015.
Patent filings trend:
- Peak filings for peptide modifications in China occurred around 2014-2018.
- Most filings target diseases such as diabetes, cancer, and autoimmune disorders.
- CN104994884 sits within this timeline, indicating a strategic emphasis on peptide stability amid a competitive landscape.
International equivalents:
- No direct foreign counterpart patents currently cited, but similar claims may be present in provisional applications.
- The patent may face challenges from prior art, especially regarding peptide stability modifications.
Strategic insights:
- The patent’s broad claims on peptide modifications and applications make it a valuable asset.
- It can block competitors from developing similar stabilized peptide drugs in China.
- There is potential to expand protection through continuations or divisional applications, targeting other disease indications or peptide modifications.
Key Takeaways
- CN104994884 claims a modified peptide with enhanced stability for therapeutic use, particularly in inflammatory and autoimmune conditions.
- Claims focus on sequence modifications, preparation, and medicinal applications, with a scope that covers a class of peptide analogs.
- The patent landscape shows high activity in peptide stabilization technologies, with significant R&D efforts in China targeting autoimmune and metabolic disorders.
- The patent’s broad claims position it as a strategic asset but could face challenges based on prior art references.
FAQs
1. Can the patent CN104994884 be enforced against international competitors?
No. It is granted in China and limited to Chinese jurisdiction. Enforcement outside China requires equivalent patent applications filed and granted in those jurisdictions.
2. Does the patent cover all peptide modifications?
No. It specifically covers peptides with the modifications disclosed, not all possible modifications or unrelated peptides.
3. Are there any known international patents similar to CN104994884?
No direct counterparts are cited, but similar stabilization strategies exist globally, particularly in the US and Europe.
4. How can the patent landscape impact R&D strategies for peptide drugs?
Patents like CN104994884 indicate strong protection opportunities for peptide stabilization technologies. Companies can focus on novel modifications or improve upon existing claims to avoid infringement.
5. What are the primary diseases targeted by this patent?
Inflammatory diseases, autoimmune disorders, and metabolic syndromes.
References
[1] State Intellectual Property Office of China. (2016). CN104994884 patent document.
